ArticleAmerican journal of translational research2025
Entecavir provides favorable virological control but minimal metabolic benefit in patients with Chronic Hepatitis B and MAFLD.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo systematically evaluate the multidimensional efficacy of entecavir in patients with Chronic Hepatitis B (CHB) complicated with metabolic-associated fatty liver disease (MAFLD), with a focus on virological response, liver function, and metabolic parameters.
methodsA retrospective analysis was conducted on 285 patients with CHB and concurrent MAFLD who received entecavir treatment at Minzu Hospital of Guangxi Zhuang Autonomous Region between January 2022 and May 2024 (MAFLD with comorbidities group). During the same period, 310 CHB patients without MAFLD served as the viral-only group. Both groups were treated with entecavir. Baseline characteristics, treatment efficacy at week 35, virological response, liver function parameters, fibrosis progression, metabolic indicators, and safety profiles were compared between the two groups.
resultsCompared with the viral-only group, patients in the MAFLD with comorbidities group exhibited significantly higher body mass index (BMI), waist circumference (WC), homeostasis model assessment of insulin resistance (HOMA-IR), fasting insulin (FINS), and triglyceride (TG) levels, as well as lower high-density lipoprotein cholesterol (HDL-C) levels, alanine aminotransferase (ALT)/aspartate aminotransferase (AST) normalization rates, hepatitis B virus (HBV) deoxyribonucleic acid (DNA) negativity rates, and hepatitis B e-antigen (HBeAg) seroconversion rates (P < 0.05). AST and GGT levels were also significantly lower in the viral-only group than in the MAFLD with comorbidities group (P < 0.05). Post-treatment fibrosis staging was more advanced in the MAFLD with comorbidities group (P < 0.05). After treatment, patients with MAFLD maintained higher HOMA-IR and TG levels and lower HDL-C levels than those without MAFLD (P < 0.05). During follow-up, the overall incidence of adverse events was 2.11% in the MAFLD with comorbidities group and 1.94% in the viral-only group, with no statistically significant difference between the groups (P > 0.05).
conclusionEntecavir can effectively control viral replication in patients with CHB combined with MAFLD. However, the recovery of liver function, improvement of steatosis and improvement of metabolic indicators were all slightly inferior to those of the non-MAFLD population, suggesting that the coexistence of MAFLD may weaken the comprehensive benefits of antiviral treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.